Navigation Links
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Date:4/24/2008

ceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward gastroenterology as well as the treatment of HIV infection and cancer. The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation (oral and subcutaneous formulations) and postoperative ileus (intravenous formulation). In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO 140, a humanized monoclonal antibody targeting the HIV entry co-receptor CCR5, which has completed phase 1b clinical studies with positive results. In the area of prostate cancer, the Company is developing a human monoclonal antibody drug conjugate - a selectively targeted cytotoxic antibody directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA.

PROGENICS DISCLOSURE NOTICE: The information contained in this document is current as of April 24, 2008. This press release contains forward-looking statements. Any statements contained herein that are not statements of historical fact may be forward-looking statements. When the Company uses the words "anticipates," "plans," "expects" and similar expressions, it is identifying forward-looking statements. Such forward-looking statements involve risks and uncertainties which may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. Such factors include, among others, the uncertainties associated with product development, the risk that clinical trials will not commence or proceed as planned, the risks and uncertainties associated with dependence upon
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
2. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
3. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
4. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
5. Wyeth Announces Executive Change in Finance Organization
6. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
7. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
9. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
10. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
11. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") today ... the ERA-EDTA Congress in London, England ... First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in Subjects ... (CKD); a Post-hoc Analysis of Patients from the ASSERT, ... Kam Kalantar-Zadeh , Professor and Chief, Division of Nephrology and Hypertension ...
(Date:6/1/2015)... , June 1, 2015  Berg, a biopharmaceutical ... biological approach, presented clinical research from its trials using ... tumors and preclinical data on triple negative breast cancer, ... American Society of Clinical Oncology (ASCO), May 29 – ... BPM 31510 is one of the first ...
(Date:6/1/2015)... LEXINGTON, Massachusetts , June 1, 2015 ... ) announces that it will be participating in the ... York, NY on Tuesday, June 2, 2015. ... in a question and answer session at 10:00 a.m. ... webcast will be available on the Presentations and Webcasts ...
(Date:6/1/2015)... May 29, 2015 Research and Markets ... the "2015 Strategies in the UK Flow ... This report presents a comprehensive analysis of ... Major issues pertaining to the French flow cytometry ... social and technological trends with significant market impact ...
Breaking Biology Technology:Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3Strategies in the UK Flow Cytometry Market 2015 2
... Platypus Technologies of suburban Madison has received ... for $200,000 from the National Cancer Institute. The grant ... rapid quantification of protein activity, useful for cancer research. ... II SBIR grant for $2.14 million from the National ...
... been calls to run government institutions as a business, ... their shareholders: taxpayers. Now schools are facing similar scrutiny. ... Behind Act have expanded the federal regulations with which ... are also demanding more budget accountability at a time ...
... Inc ., a provider information management systems and services ... a definitive agreement to acquire BillMatrix Corp ., ... , ,BillMatrix, founded in 1994, provides billers with an ... immediate credit for bills paid online or over the ...
Cached Biology Technology:Looking to software to manage the business of education 2Looking to software to manage the business of education 3Looking to software to manage the business of education 4
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... SALT LAKE CITYResearchers have discovered two enzymes that, when ... cancer. Manipulating these enzymes genetically might lead to targeted ... tumors. "We could conceivably reactivate a completely normal ... could prevent the growth of a tumor if reactivated," ...
... crimefighter who protected the innocent from pirates, hijackers and ... its costumed namesake, this electromagnetic phantoma carbon and polymer ... the National Institute of Standards and Technology (NIST) for ... The NIST phantom serves as a mannequin in a ...
... Researchers at The University of Texas School of Public Health ... of community-acquired antibiotic-resistant Staph ylococcus aureus ... (PVL). The Panton Valentine leukocidin is made ... is typically produced by community-acquired methicillin-resistant S. aureus ...
Cached Biology News:Newly found enzymes may play early role in cancer 2Electromagnetic phantom exorcises specters of metal detector tests 2UT Public Health researchers find link to severe Staph infections 2
... has the ability to quickly and accurately copy ... a perfect candidate for inclusion in these high ... supplied with all the Cartesian products to allow ... ability to copy plates in seconds or reformat ...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... Label IT siRNA Tracker Intracellular Localization ... a straight forward approach to directly ... design, in an efficient yet non-destructive ... Subcellular localization and functional inhibition of ...
... numbers as a trigger, precisely isolates target ... and research of natural compounds. Key features ... operation. Switching between modes is simple - ... provides a quick solution for chemists optimizing ...
Biology Products: